{"id":"NCT03820986","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)","officialTitle":"A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-12","primaryCompletion":"2023-01-18","completion":"2024-11-01","firstPosted":"2019-01-29","resultsPosted":"2024-01-17","lastUpdate":"2024-12-02"},"enrollment":674,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Malignant Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Lenvatinib","otherNames":["MK-7902","E7080","LENVIMA®"]},{"type":"DRUG","name":"Placebo for lenvatinib","otherNames":[]}],"arms":[{"label":"Pembrolizumab+Lenvatinib","type":"EXPERIMENTAL"},{"label":"Pembrolizumab+Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced melanoma.\n\nThe primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Overall Survival (OS). For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.","primaryOutcome":{"measure":"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to approximately 46 months","effectByArm":[{"arm":"Pembrolizumab+Lenvatinib","deltaMin":10.1,"sd":null},{"arm":"Pembrolizumab+Placebo","deltaMin":4.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0295"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":29},"locations":{"siteCount":119,"countries":["United States","Australia","Austria","Brazil","Canada","Chile","China","France","Germany","Israel","Italy","Poland","South Africa","South Korea","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":119,"n":332},"commonTop":["Hypertension","Diarrhoea","Hypothyroidism","Asthenia","Fatigue"]}}